The Stroke Prognosis Instrument II (SPI-II) - A clinical prediction instrument for patients with transient ischemia and nondisabling ischemic stroke

Background and Purpose-In 1991 we developed the Stroke Prognosis Instrument (SPI-I) to stratify patients with transient ischemic attack or ischemic st roke by prognosis for stroke or death in 2 years. In this article we valida te and improve SPI-I (creating SPI-II). Methods-To validate SPI-I, we applied it to 4 test cohorts and calculated p ooled outcome rates. To create SPI-II, we incorporated new predictive varia bles identified in I of the test cohorts and validated it in the other 3 co horts. Results-For SPI-I, pooled rates tall 4 test cohorts) of stroke or death wit hin 2 years in risk groups I, II, and III were 9%, 17%, and 24%, respective ly (P<0.01, log-rank test). SPI-II was created by adding congestive heart f ailure and prior stroke to SPI-I. Each patient's risk group was determined by the total score for 7 factors: congestive heart failure (3 points); diab etes (3 points); prior stroke (3 points); age >70 years (2 points), stroke for the index event (not transient ischemic attack) (2 points); hypertensio n (1 point); and coronary artery disease (1 point). Risk groups I, II, and III comprised patients with 0 to 3, 4 to 7, and 8 to 15 points, respectivel y. For SPI-I, pooled rates (3 cohorts excluding the SPI-II development coho rt) of stroke or death within 2 years in risk groups I, II, and III were 9% , 17%, and 23%, respectively. For SPI-II, pooled rates were 10%, 19%, and 3 1%, respectively. In receiver operator characteristic analysis, the area un der the curve was 0.59 (95% CI, 0.57 to 0.60) for SPI-I and 0.63 (95% CI, 0 .63 to 0.65) for SPI-II, confirming the better performance of the latter. Conclusions-Compared with SPI-I, SPI-II achieves greater discrimination in outcome rates among risk groups. SPI-II is ready for use in research design and may have a role in patient counseling.